These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30013791)

  • 1. HbA1c and hypoglycaemia in intensively treated type 2 diabetes: a retrospective cohort study in primary care.
    Malawana M; Kerry S; Mathur R; Robson J
    JRSM Open; 2018 Jul; 9(7):2054270418773669. PubMed ID: 30013791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethnic variations in the risk of hypoglycaemia among people with Type 2 diabetes prescribed insulins and/or sulfonylureas: a historical cohort study using general practice-recorded data.
    Malawana M; Hutchings A; Mathur R; Robson J
    Diabet Med; 2018 Dec; 35(12):1707-1715. PubMed ID: 30264528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Mar; 352():i1450. PubMed ID: 27029547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
    van Dalem J; Brouwers MC; Stehouwer CD; Krings A; Leufkens HG; Driessen JH; de Vries F; Burden AM
    BMJ; 2016 Jul; 354():i3625. PubMed ID: 27413017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population-based cohort study.
    Dimakos J; Cui Y; Platt RW; Renoux C; Filion KB; Douros A
    Diabetes Obes Metab; 2024 Aug; 26(8):3088-3098. PubMed ID: 38698651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early glycaemic changes after initiation of oral antidiabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes.
    Ghouse J; Blanche P; Skov MW; Lind B; Vaag A; Kanters JK; Svendsen JH; Køber L; Olesen MS; Gerds TA; Holst AG; Nielsen JB
    Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):486-495. PubMed ID: 32614428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival.
    Currie CJ; Holden SE; Jenkins-Jones S; Morgan CL; Voss B; Rajpathak SN; Alemayehu B; Peters JR; Engel SS
    Diabetes Obes Metab; 2018 Apr; 20(4):821-830. PubMed ID: 29119713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study.
    Zaccardi F; Ling S; Lawson C; Davies MJ; Khunti K
    Diabetologia; 2020 Oct; 63(10):2129-2139. PubMed ID: 32728893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial.
    Furler J; O'Neal D; Speight J; Blackberry I; Manski-Nankervis JA; Thuraisingam S; de La Rue K; Ginnivan L; Doyle R; Holmes-Truscott E; Khunti K; Dalziel K; Chiang J; Audehm R; Kennedy M; Clark M; Jenkins A; Lake AJ; Januszewski AS; Catchpool M; Liew D; Clarke P; Best J
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):17-26. PubMed ID: 31862147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both hypo- and hyperglycaemia are associated with increased fracture risk in Japanese people with type 2 diabetes: the Fukuoka Diabetes Registry.
    Komorita Y; Iwase M; Fujii H; Ohkuma T; Ide H; Yoshinari M; Oku Y; Nakamura U; Kitazono T
    Diabet Med; 2020 May; 37(5):838-847. PubMed ID: 31556147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.
    Fournier M; Germe M; Theobald K; Scholz GH; Lehmacher W
    Ger Med Sci; 2014; 12():Doc14. PubMed ID: 25332702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD.
    Chow LS; Chen H; Miller ME; Marcovina SM; Seaquist ER
    Diabetologia; 2015 Jun; 58(6):1160-6. PubMed ID: 25652389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2).
    Ghosh S; Tiwaskar M; Chawla R; Jaggi S; Asirvatham A; Panikar V
    Diabetes Ther; 2020 Oct; 11(10):2257-2268. PubMed ID: 32779100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.